Aptamers in Bordeaux, 24–25 June 2016
by
Jean-Jacques Toulmé 1,*
, Paloma H. Giangrande 2, Günter Mayer 3, Beatrix Suess 4, Frédéric Ducongé 5, Bruce Sullenger 6, Vittorio De Franciscis 7, Fabien Darfeuille 1 and Eric Peyrin 8
Jean-Jacques Toulmé 1,*, Paloma H. Giangrande 2, Günter Mayer 3, Beatrix Suess 4, Frédéric Ducongé 5, Bruce Sullenger 6, Vittorio De Franciscis 7, Fabien Darfeuille 1 and Eric Peyrin 8
1
ARNA Laboratory, Inserm U1212, CNRS UMR5320, University of Bordeaux, Bordeaux 33076, France
2
Department of Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
3
Unit Chemical Biology and Medicinal Chemistry, University of Bonn, Bonn 53121, Germany
4
Department of Biology, Technical University Darmstadt, Darmstadt 64287, Germany
5
CEA, DRF, I2BM, MIRCen, CNRS UMR 9199, University Paris Saclay, Fontenay aux Roses 92265, France
6
Department of Surgery, Duke University, Durham, NC 27710, USA
7
Institute of Experimental Endocrinology and Oncology, CNR, Naples 80145, Italy
8
Department of Molecular Pharmacochemistry, CNRS UMR5063, University Grenoble Alpes, Saint Martin d’Hères 38400, France
*
Author to whom correspondence should be addressed.
Academic Editors: Alfredo Berzal-Herranz and Cristina Romero-López
Pharmaceuticals 2017, 10(1), 14; https://doi.org/10.3390/ph10010014
Received: 16 November 2016 / Revised: 12 January 2017 / Accepted: 13 January 2017 / Published: 20 January 2017
(This article belongs to the Special Issue Aptamers: Biomedical Interest and Applications)
The symposium covered the many different aspects of the selection and the characterization of aptamers as well as their application in analytical, diagnostic and therapeutic areas. Natural and artificial riboswitches were discussed. Recent advances for the design of mutated polymerases and of chemically modified nucleic acid bases that provide aptamers with new properties were presented. The power of aptamer platforms for multiplex analysis of biomarkers of major human diseases was described. The potential of aptamers for the treatment of cancer or cardiovascular diseases was also presented. Brief summaries of the lectures presented during the symposium are given in this report. A second edition of “Aptamers in Bordeaux” will take place on September 2017 (http://www.aptamers-in-bordeaux.com/ ).
View Full-Text
Keywords:
aptamer; in vitro selection; SELEX; riboswitch; oligonucleotide; biosensor; cardiovascular; cancer; cell-targeted aptamers; imaging; synthetic biology
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Toulmé, J.-J.; Giangrande, P.H.; Mayer, G.; Suess, B.; Ducongé, F.; Sullenger, B.; De Franciscis, V.; Darfeuille, F.; Peyrin, E. Aptamers in Bordeaux, 24–25 June 2016. Pharmaceuticals 2017, 10, 14.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
